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BACKGROUND: The recent introduction of a dynamic nuclear polarisation technique has permitted noninvasive imaging of tumour cell
metabolism in vivo following intravenous administration of
13C-labelled cell substrates.
METHODS: Changes in hyperpolarised [1-
13C]pyruvate and [1,4-
13C2]fumarate metabolism were evaluated in both MDA-MB-231 cells
and in implanted MDA-MB-231 tumours following doxorubicin treatment.
RESULTS: Treatment of MDA-MB-231 cells resulted in the induction of apoptosis, which was accompanied by a decrease in
hyperpolarised
13C label flux between [1-
13C]pyruvate and lactate, which was correlated with a decrease in the cellular NAD(H)
coenzyme pool. There was also an increase in the rate of fumarate conversion to malate, which accompanied the onset of cellular
necrosis. In vivo, the decrease in
13C label exchange between pyruvate and lactate and the increased flux between fumarate and
malate, following drug treatment, were shown to occur in the absence of any detectable change in tumour size.
CONCLUSION: We show here that the early responses of a human breast adenocarcinoma tumour model to drug treatment can be
followed by administration of both hyperpolarised [1-
13C]pyruvate and [1,4-
13C2]fumarate. These techniques could be used,
therefore, in the clinic to detect the early responses of breast tumours to treatment.
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There has been substantial growth and investment in drug
discovery and development programmes in oncology in recent
years, with the aim of producing therapeutics targeted at the
spectrum of genetic abnormalities found in cancer (Hu et al, 2000;
Semenza, 2003; Bryant et al, 2005). This rapid expansion has
moved the field of clinical oncology closer to the realisation
of personalised medicine, in which patients receive drugs,
individually or in combination, that are tailored to their specific
disease. The delivery of this approach should be facilitated by
noninvasive imaging methods that allow an early assessment of
treatment response, identifying unsuccessful treatments at an early
stage and enabling the selection of more effective treatment
(reviewed in Brindle (2008a)).
Currently, tumour treatment responses are assessed from
reductions in tumour size (Eisenhauer et al, 2009). However, this
approach lacks sensitivity and many weeks may elapse before a
change in size is detected (Neves and Brindle, 2006; Weissleder and
Pittet, 2008; Brindle, 2008a). In some cases, for example with
cytostatic therapies, there may be no change in size despite a
positive response to treatment (Brindle, 2008a). Measurements of
tumour physiology or biochemistry, however, can give a much
earlier indication of treatment response. Positron emission tomo-
graphy (PET) measurements of the uptake of the glucose analogue
[
18F] 2-fluoro-2-deoxy-D-glucose (FDG) are being used increas-
ingly in the clinic to stage disease and provide early evidence of
treatment response (Eisenhauer et al, 2009).
MRS, particularly
1H MRS, can also be used to detect the
metabolic changes that accompany a positive response to
treatment (Aboagye and Bhujwalla, 1999; Glunde et al, 2006).
The relative lack of sensitivity of MRS, however, limits the spatial
and temporal resolution of
1H spectroscopic imaging experiments
and in many cases only single voxel studies are performed
(Hu et al, 2009). Although
1H MRS experiments are performed
widely in the clinic, this lack of sensitivity has limited their routine
use. This situation may change with the recent introduction
of a dynamic nuclear polarisation (DNP) technique that can
increase sensitivity in the solution state
13C MRS experiment by
410000-fold (Ardenkjaer-Larsen et al, 2003). The enormous gain
in sensitivity means that, following injection of a hyperpolarised
13C-labelled cell substrate, there is sufficient signal to image the
molecule in vivo, and, more importantly, its metabolic conversion
into other cell metabolites. Whereas
1H MRS measurements
provide a largely static picture of the levels of tissue metabolites,
this labelling technique enables dynamic imaging of cellular
metabolism. The principal drawback of the method, however,
is the short half-life of the polarisation; for [1-
13C]pyruvate this
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sis B30s in vivo, which means that the material must be injected
and imaged within B5min. Thus, in order to image metabolism
using this technique, the hyperpolarised
13C-labelled substrate
must be taken up rapidly by the cell and its subsequent
metabolism must be very fast. Even then, it is often only possible
to monitor a single enzyme-catalysed reaction (Gallagher et al,
2009a). Nevertheless, the technique has already shown promise for
detecting treatment response in tumours (Day et al, 2007; Witney
et al, 2009).
The exchange of hyperpolarised
13C label between
[1-
13C]pyruvate and lactate, in the reaction catalysed by lactate
dehydrogenase (LDH), was shown to decrease in a drug-treated
murine lymphoma in vivo (Day et al, 2007), where decreased label
flux was due to a number of factors, including: DNA damage-
mediated activation of polyADP-ribose polymerase (PARP) and
consequent depletion of the NAD(H) coenzyme pool, a loss of LDH
activity, and a reduction in tumour cellularity (Day et al, 2007;
Witney et al, 2009). A similar study in the same tumour model
using [1,4-
13C2]fumarate, showed that the rate of the fumarase
catalysed conversion of fumarate to malate was a measure of
subsequent drug-induced cellular necrosis (Gallagher et al, 2009b).
With a clinical trial using hyperpolarised [1-
13C]pyruvate about to
start in prostate cancer (Brindle, 2008b), there is a reasonable
expectation that the technique could translate to the clinic, where it
offers a new functional imaging approach to detect early tumour
responses to treatment.
We show here, in a model of human breast adenocarcinoma,
that a combination of hyperpolarised [1-
13C]pyruvate and
[1,4-
13C2]fumarate can be used to detect response to doxorubicin
treatment before there is any detectable change in tumour size.
There was a decrease in labelled lactate production, reflecting a
DNA damage response and initiation of the apoptotic program,
and an increase in labelled malate production, reflecting the onset
of cellular necrosis.
MATERIALS AND METHODS
Cell culture
MDA-MB-231 cells (European Collection of Cell Cultures,
Salisbury, Wiltshire, UK) were grown in RPMI 1640 media,
supplemented with 10% fetal calf serum, 2mML -glutamine,
100Uml
 1 penicillin and 100mgml
 1 streptomycin (Invitrogen,
Paisley, Refrewshire, UK). Cell number and viability were moni-
tored using trypan blue staining. Cell death was induced
by addition of doxorubicin (1mgml
 1 final concentration;
Sigma-Aldrich Co. Ltd, Poole, Dorset, UK).
Flow cytometry
Apoptosis and necrosis were measured by flow cytometry. Cells
were trypsinised (0.25% trypsin; 1mM EDTA) and harvested by
centrifugation (1300g, 3min). Detached cells present in the media
before trypsinisation were retained and pooled with the trypsinised
cells. Cell pellets (1 10
6 cells) were washed once in ice-cold
HEPES-buffered saline (10mM HEPES, 140mM NaCl, 2.5mM CaCl2,
pH 7.4) and resuspended in 100ml of the same buffer. Annexin
V-Pacific Blue (5ml per 100ml of cell suspension) and SYTOX Red
(Invitrogen) (5nM) were added to the cells and incubated for
15min at 201C. The resulting mixture was washed once in ice-cold
HEPES-buffered saline, kept briefly on ice and then analysed in an
LSRII cytometer (BD Biosciences, Rockville, MD, USA), with
20000 cells counted per event. Viable cells were identified as cells
that stain with neither annexin V nor SYTOX Red; apoptotic cells
as cells that stain with annexin V, but not SYTOX Red; and
necrotic cells as cells that stain with both annexin V and SYTOX
Red. Cellular NADH content was assessed from measurements of
autofluorescence at 455nm following excitation at 350nm (Day
et al, 2007; Witney et al, 2009). Cytosolic NADH has been shown
previously to make a significant contribution to this autofluores-
cence (Aubin, 1979) and it is the cytosolic, rather than the
mitochondrial NAD(H) pool, that is depleted the following
activation of PARP (Ying et al, 2005).
Western blots
PolyADP-ribose polymerase cleavage was assessed by western
blotting as described previously (Witney et al, 2009). Membranes
were probed using polyclonal rabbit anti-PARP1 antibody (Abcam,
Cambridge, Cambridgeshire, UK, 1:1000). A rabbit anti-actin
antibody (Sigma-Aldrich Co. Ltd, 1:1000) was used as a loading
control and a peroxidase-conjugated donkey anti-rabbit IgG
antibody (Jackson ImmunoResearch Europe Ltd., Newmarket,
UK, 1:10000) as the secondary antibody. Proteins were visualised
using the ECLplus kit (GE Healthcare, Chalfont St Giles, Bucks,
UK). Blots were scanned (PowerLook III, Umax Systems GmbH,
Willich, Germany) and signal quantification was performed by
densitometry using scanning analysis software (TotalLab TL120,
Nonlinear Dynamics, Newcastle upon Tyne, UK).
[1-
13C]Pyruvate and [1,4-
13C2]fumarate hyperpolarisation
A4 4m gs a m p l eo f9 1 %[ 1 -
13C]pyruvic acid, containing 15mM of the
trityl radical OXO63 (GE Healthcare, Little Chalfont, UK) and 1.5mM
ProHance (Bracco Diagnostics Inc, Princeton, NJ, USA), was prepared
with a 40mg sample of [1,4-
13C2]fumaric acid dissolved in DMSO,
containing 15mM of the trityl radical AH-111501 and 0.5mM of a
gadolinium chelate, 3-Gd, (GE Healthcare, Little Chalfont, UK).
Aliquots (10ml) of [1,4-
13C2]fumaric acid were dropped into liquid
nitrogen to form pellets, which were placed in the DNP polariser with
previously frozen [1-
13C]pyruvic acid. Polarisation was performed
using a microwave source at 93.982GHz and 100mW for 1h. The
frozen sample was dissolved at 1801Cu s i n g6 m lo fa4 0 m M
phosphate buffer, containing 120mM NaOH and 100mgl
 1 EDTA.
The dissolved solution contained 20mM [1,4-
13C2]fumarate and
75mM [1-
13C]pyruvate. The sample was dissolved in o5s and
polarisation levels were between 18–25%, determined by comparing
the signal intensity from the hyperpolarised sample to that observed
at thermal equilibrium (Gallagher et al, 2008). For in vivo studies,
[1-
13C]pyruvic acid and [1,4-
13C2]fumaric acid pellets were hyper-
polarised separately, with 40mM HEPES, 94mM NaOH, 30mM NaCl,
100mgl
 1 EDTA and 40mM phosphate buffer, 40mM NaOH, 50mM
NaCl, 100mgl
 1 EDTA used as the dissolution buffers, respectively.
13C MRS measurements on cells
Cells (2–6 10
7) were examined in a 10-mm NMR tube, using a
broadband probe (Varian NMR Instruments, Palo Alto, CA, USA)
in a 9.4-T vertical wide-bore magnet (Oxford Instruments,
Oxfordshire, UK) interfaced to a Varian INOVA console (Varian
NMR Instruments, Paulo Alto, CA, USA). The sample temperature
was maintained at 371C. Hyperpolarised [1-
13C]pyruvate (75mM),
hyperpolarised [1,4-
13C2]fumarate (20mM) and nonhyperpo-
larised, unlabelled lactate (75mM) were injected into the cell
suspension and single transient
13C spectra were acquired every
second for 240s, using a 61 flip angle pulse and a spectral width of
32kHz. The area under each peak was used to calculate
concentration of the labelled metabolites. The two inequivalent
malate peaks,
13C-labelled at the C-1 and C-4 position, were
combined to produce a single measurement of intensity (Gallagher
et al, 2009b). The peak intensities of hyperpolarised metabolites
were fitted to two-site exchange models describing the fluxes of
hyperpolarised
13C label between pyruvate and lactate (kP), and
fumarate and malate (kF; Day et al, 2007).
Detection of treatment response in breast adenocarcinoma
TH Witney et al
1401
British Journal of Cancer (2010) 103(9), 1400–1406 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sTumour implantation
Female severe combined immunodeficiency mice were purchased
at 6–8 weeks of age from Harlan UK Ltd (Bicester, UK). Tumour
cells (1 10
7) were injected subcutaneously into the shaved flanks
of mice. Tumour size was measured using callipers and is reported
as the product of the two largest perpendicular diameters (mm
2).
Mice were imaged 24h before treatment with an i.v. injection
of 10mg doxorubicin per kg body weight and at 24 and 48h
post-treatment. All procedures were carried out in accordance with
the Animals (Scientific Procedures) Act of 1986 (UK) and were
designed with reference to the UK Co-ordinating Committee on
Cancer Research Guidelines for the Welfare of Animals in
Experimental Neoplasia.
13C MRS and
1H MRI measurements on tumours
Mice were anesthetised with an intraperitoneal injection of 10ml
per kg body weight of a 5:4:31 mixture of Hypnorm (VetaPharma
Ltd, Leeds, West Yorkshire, UK), Hypnovel (Roche, Basel,
Switzerland) and saline and a catheter inserted into a tail vein.
A 25mm diameter surface coil tuned to
13C (100MHz) was
positioned over the tumour. The entire assembly was placed in a
quadrature
1H-tuned volume coil (Varian), in a 9.4-T vertical
wide-bore magnet. Transverse
1H images were acquired from the
tumour using a spin-echo pulse sequence (repetition time, 1.5s;
echo time, 30ms; field of view, 32mm 32mm; data matrix,
256 256; slice thickness, 2mm; 11 slices). Following injection of
hyperpolarised [1-
13C]pyruvate, which was accomplished within
3s, 128 single transient spectra were collected from a 6mm tumour
slice over a period of 128s (every sixteenth spectrum was collected
from the entire sensitive volume of the surface coil). Spectra were
acquired using a slice-selective 600ms sinc pulse, with a nominal
flip angle of 51. C-1 lactate and pyruvate peak intensities were
fitted to the modified Bloch equations for two-site exchange to
obtain an apparent rate constant for label exchange between
pyruvate and lactate (kP), as described previously (Day et al, 2007).
Following [1-
13C]pyruvate injection, [1,4-
13C2]fumarate was
polarised and injected into the animal, which was still anesthetised.
This was achieved within 1h of the previous injection. Owing
to the low-malate signals observed, dynamic measurements of
fumarate conversion to malate could not be performed in vivo.
Instead, a single
13C spectrum, collected from a 6mm tumour slice,
was acquired 20s after injection of 0.2ml fumarate using a
nominal flip angle of 201; a time at which the maximum malate
peak intensity had been observed in a previous dynamic study in a
drug-treated murine lymphoma tumour (Gallagher et al, 2009b).
Data were expressed as the malate/fumarate ratio, calculated from
the intensities of the [1,4-
13C2]fumarate resonance and the
combined resonances from [1-
13C]malate and [4-
13C]malate.
Statistics
Results are expressed as the mean±s.d. Significant differences
between values were determined using a Mann–Whitney non-
parametric test. Statistical analysis was performed using GraphPad
Prism version 5.0 for windows (GraphPad Software, San Diego,
CA, USA). Differences between treatment groups were considered
significant if Po0.05.
RESULTS
Measurement of cell death following drug treatment
in vitro
Drug-induced apoptosis and necrosis of human breast cancer cells
(MDA-MB-231) were assessed by flow cytometry, following
staining of the cells with Annexin V-Pacific Blue and SYTOX Red,
respectively (Figure 1). There were significant increases in
apoptosis and necrosis by 48h after treatment with doxorubicin,
which is a commonly used chemotherapeutic drug (Gewirtz, 1999;
Figure 1A). Annexin V binding to apoptotic cells correlated with
the induction of caspase-3 activity at 48h, as indicated by PARP
cleavage (Kaufmann et al, 1993). There was a small decrease in the
level of intact PARP at 48h, with a 26 and 20% decrease compared
with cells at 0h in two independent experiments, with the level of
uncleaved PARP becoming almost undetectable at 72h (Figure 1A,
inset). The apoptotic fraction peaked at 72h, before declining at
96h, whereas the necrotic fraction was increased at 72h and
further increased at 96h.
Monitoring treatment response in cells with
hyperpolarised [1-
13C]pyruvate and [1,4-
13C2]fumarate
Addition of hyperpolarised [1-
13C]pyruvate and [1,4-
13C2]fuma-
rate to MDA-MB-231 cells, resulted in an increase in the lactate
carboxyl signal intensity as the hyperpolarised
13C label was trans-
ferred from pyruvate, followed by a decrease in signal intensity due
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04 87 29 6
PARP
Actin
Apoptosis
Necrosis
C
e
l
l
 
f
r
a
c
t
i
o
n
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
C
e
l
l
u
l
a
r
 
N
A
D
(
H
)
 
l
e
v
e
l
s
120
100
80
60
40
20
0
Time post-treatment (h)
02 4 4 8 72 96 120
Time post-treatment (h)
0 24 48 72 96 120
Figure 1 Cell death and NADH depletion in MDA-MB-231 cells
following doxorubicin treatment. (A) Cell fraction undergoing apoptosis
(’) and necrosis (J), as determined by flow cytometry. Apoptotic cells
were detected using annexin V Pacific Blue (l Ex/Em¼410/455) and
necrotic cells using SYTOX Red nuclear staining (l Ex/Em¼640/658).
Inset: Representative western blot of PARP expression in MDA-MB-231
cells following doxorubicin treatment. Actin was used as a loading control.
(B) Changes in the cellular NADH pool following treatment. The NADH
pool was measured by recording changes in UV autofluorescence, as
detected by flow cytometry (l Ex/Em¼350/455).
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sto decay of the polarisation (Figures 2 and 3). At 72h after
doxorubicin treatment, there was a 48% decrease (n¼4; Po0.01)
in
13C label exchange between pyruvate and lactate (Figures 2, 3A
and B), which was accompanied by a 77% decrease in NADH
autofluorescence (Po0.01; Figure 1B). At 96h after drug treatment
there was a 72% (n¼4; Po0.01) decrease in label exchange,
by which time the NADH autofluorescence had decreased by
89±1% (Po0.01). There was no detectable flux of label from
hyperpolarised [1,4-
13C2]fumarate to hyperpolarised [1,4-
13C2]-
labelled malate until 72h after doxorubicin treatment (Figure 2),
when the apparent rate constant (kF) for label flux was
2.8 10
 4±1.4 10
 4s
 1 (n¼4). By 96h, the rate constant had
increased by 55% to 6.1 10
 4±0.8 10
 4s
 1 (n¼4; Po0.01;
Figure 3C and D). There was a good correlation between the extent
of cellular necrosis, and the rate constant describing label flux
between fumarate and malate (R
2¼0.96; Figure 4).
Monitoring treatment response in tumours with
hyperpolarised [1-
13C]pyruvate and [1,4-
13C2]fumarate
Intravenous injection (0.2ml) of co-hyperpolarised [1-
13C]pyru-
vate (75mM) and [1,4-
13C2]fumarate (20mM) into MDA-MB-231
tumour-bearing mice resulted in the appearance of signals from
[1-
13C]pyruvate, [1-
13C]lactate and [1,4-
13C2]fumarate in the
tumours. There were no detectable signals from [1,4-
13C2]malate,
because of their masking by resonances from labelled lactate
and pyruvate hydrate (data not shown). For this reason,
[1-
13C]pyruvate and [1,4-
13C2]fumarate experiments were
performed separately. There was a 49% decrease in pyruvate–
lactate exchange at 24h after doxorubicin treatment, where the
rate constant (kP) decreased from 0.075±0.002s
 1 in untreated
tumours to 0.038±0.025s
 1 (P¼0.15; n¼3 animals). By 48h,
the rate constant had decreased by 73% to 0.020±0.002s
 1
(P¼0.0017, n¼3). There was no significant change in tumour
size during this period, with the mean tumour volume of
68.0±12.9mm
2 (n¼10 animals) in untreated animals remaining
at 65.9±17.3mm
2 (n¼6) and 62.5±16.3mm
2 (n¼6) at 24 and
48h post-treatment, respectively. Representative spectra from
an untreated tumour and a tumour at 48h after doxorubicin
treatment are shown in Figure 5A. The maximum amplitude of the
[1,4-
13C2]malate signals relative to the signal from [1,4-
13C2]fumarate
20s post-injection increased from 0.017±0.013 in untreated tumours
to 0.090±0.050 at 24h after doxorubicin treatment (n¼4; Po0.05),
a 5.4-fold increase (Figure 5B).
DISCUSSION
Imaging currently has an important role in the management of
breast cancer patients by enabling assessment of treatment
response following primary or neoadjuvant therapy. Therapeutic
response is assessed primarily by measurements of tumour
shrinkage, using a combination of computed tomography (CT)
and/or MRI (reviewed in Ollivier et al (2005)). However, there are
problems with these imaging modalities. CT has the advantages of
simplicity, speed and availability, however, changes in tumour size
are frequently overestimated in diffuse or multinodular tumours
(Ollivier et al, 2005). Changes in tumour size can also be
overestimated by MRI, particularly with smaller tumours and if
there is surrounding tissue oedema (Merchant et al, 1993).
Dynamic contrast-enhanced MRI can provide further diagnostic
information, with the intensity of contrast enhancement shown to
predict the presence of residual tumour after preoperative
chemotherapy (Gilles et al, 1994). There is a need, however, to
develop imaging methods that can detect treatment response more
sensitively and before there is any change in tumour size.
FDG-PET is being used increasingly in the clinic as a functional
imaging technique for detection, staging and early response
monitoring in breast cancer (Eubank and Mankoff, 2005).
Although currently most useful as a staging tool, initial studies
have shown FDG-PET to be capable of predicting pathological
response in patients with locally advanced breast cancer following
a single course of neoadjuvant chemotherapy (Biersack et al, 2004;
Krak et al, 2004). However, the presence of infected or inflamed
tissue, and high uptake by infiltrating immune cells can mask
changes in tumour FDG uptake (Strauss, 1996; Zhuang et al, 2005).
Patients also receive a high radiation dose, with scans being costly,
time-consuming and are only available in a few selected centres.
Complementary methods for the detecting treatment response in
1
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Figure 2 Representative
13C spectra of cell suspensions 15s after the
addition of 75mM hyperpolarised [1-
13C]pyruvate, 20mM hyperpolarised
[1,4-
13C2]fumarate and 75mM unlabelled lactate. Cells were either
untreated (A), or had been treated with doxorubicin for 72h (B)o r
96h (C). The labelled peaks are: 1, [1-
13C]lactate; 2, [1,4-
13C2]malate;
3, [1-
13C]pyruvate hydrate; 4, [1,4-
13C2]fumarate; 5, [1-
13C]pyruvate.
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sbreast cancer are therefore still required that provide alternative
biological readouts that can be used in conjunction with existing
methods in a multimodality approach.
Treatment of murine EL-4 lymphoma cells with a topoisomerase
II inhibitor and DNA damaging agent, etoposide, was shown
previously to inhibit the rate of hyperpolarised
13C label exchange
between [1-
13C]pyruvate and lactate, catalysed by the enzyme
LDH. The decreased exchange was explained by induction of
a DNA damage response and consequent induction of PARP,
for which the coenzyme NAD
þ is a substrate (Day et al, 2007;
Witney et al, 2009). We have shown here that doxorubicin
treatment of the oestrogen receptor negative-human breast
cancer cell line, MDA-MB-231, in vitro resulted in a marked
decrease in the rate of hyperpolarised
13C label exchange between
[1-
13C]pyruvate and lactate and that this was correlated with a
decrease in the concentration of the cellular NAD(H) coenzyme
pool. Doxorubicin, like etoposide, is a topoisomerase II inhibitor
and a DNA damaging agent that induces PARP activation
(Munoz-Gamez et al, 2005). Therefore, this hyperpolarised
[1-
13C]pyruvate method for detecting response to genotoxic agents
would appear to be generally applicable to other tumour types.
The hyperpolarised [1-
13C]pyruvate experiment shows that the
tumour cell has responded to treatment, but not that it has died.
Moreover, it provides ‘negative contrast’, in that there is a decrease
in lactate signal intensity in those tumours that have responded to
treatment (Day et al, 2007; Witney et al, 2009). Such a decrease in
lactate signal could also be due to other factors, such as reduced
delivery of pyruvate to the tumour. In contrast, hyperpolarised
13C-labelled [1,4-
13C2]fumarate provides positive contrast and
appears to be a marker of cell death (Gallagher et al, 2009b).
Fumarate shows relatively slow plasma membrane transport, and
thus, in viable cells there is no detectable conversion of fumarate to
malate within the relatively short lifetime of the
13C polarisation.
However, in necrotic cells, where the plasma membrane perme-
ability barrier has been compromised, fumarate is rapidly
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Figure 3 Effect of doxorubicin-induced cell death on flux of hyperpolarised
13C label between pyruvate and lactate, and between fumarate and malate in
an MDA-MB-231 cell suspension. (A) [1-
13C]lactate peak intensities after addition of 75mM hyperpolarised [1-
13C]pyruvate, 20mM hyperpolarised
[1,4-
13C2]fumarate and 75mM unlabelled lactate to MDA-MB-231 cell suspensions that had been treated with doxorubicin or were untreated. Spectra were
corrected for cell number and scaled to the initial pyruvate signal intensity to correct for variation in polarisation levels. Shaded regions represent 1 s.e.m.
(n¼4 for all treatment groups). (B) Changes in [1-
13C]pyruvate–[1-
13C]lactate exchange rate constant following doxorubicin treatment. The exchange rate
constant (kP) was derived by fitting changes in signal peak intensity to the modified Bloch equations for two-site exchange. Mean values (n¼4) and s.d. are
shown (*Po0.05, **Po0.01). (C) Total [1,4-
13C2]malate peak intensities after addition of 75mM hyperpolarised [1-
13C]pyruvate, 20mM hyperpolarised
[1,4-
13C2]fumarate and 75mM unlabelled lactate to MDA-MB-231 cell suspensions that had been treated with doxorubicin or were untreated. Spectra were
corrected for cell number and scaled to the initial fumarate signal intensity to correct for variation in polarisation levels. Shaded regions represent 1 s.e.m.
(n¼4 for all treatment groups). (D) Changes in the rate constant describing hyperpolarised
13C label flux between [1,4-
13C2]fumarate and [1,4-
13C2]malate
following doxorubicin treatment. The rate constant (kF) was derived by fitting changes in signal peak intensities to the modified Bloch equations for two-site
exchange. Mean values (n¼4) and s.d. are shown (*Po0.05, **Po0.01).
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Figure 4 Correlation between cellular necrosis and the rate constant
describing hyperpolarised
13C label flux between [1,4-
13C2]fumarate and
malate. Necrosis was monitored by flow cytometric analysis of SYTOX Red
dead cell staining (l Ex/Em¼640/658). In separate experiments, the rate
constant (kF) was derived by fitting changes in signal peak intensities to the
modified Bloch equations for two-site exchange. Mean values (n¼3–4)
and s.d. are shown.
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13C2]malate signal
provides a positive marker of tumour cell necrosis. Treatment of
MDA-MB-231 cells with doxorubicin resulted in the production of
significant levels of labelled malate by 72h after drug treatment, a
time at which there was also a significant decrease in the rate of
labelled lactate production. There was no detectable labelled
malate produced in untreated cells. The rate of labelled malate
production showed a good correlation with the level of tumour cell
necrosis, as has been observed previously (Gallagher et al, 2009b).
As with the hyperpolarised [1-
13C]pyruvate method for detecting
response to genotoxic agents, these experiments have demon-
strated that the hyperpolarised [1,4-
13C2]fumarate experiment
could be a generic method for detecting tumour cell death post-
treatment.
Experiments with hyperpolarised [1-
13C]pyruvate and
[1,4-
13C2]fumarate were also performed in implanted MDA-MB-
231 tumours, where we have shown a response to doxorubicin
treatment in the absence of any detectable change in tumour size.
Co-hyperpolarised [1-
13C]pyruvate and [1,4-
13C2]fumarate pre-
parations could not be used in vivo as malate production was
masked by overlapping signals from lactate and pyruvate hydrate
formed from the labelled pyruvate in these lower resolution
13C spectra. When the pyruvate was injected alone, a significant
decrease in pyruvate–lactate exchange was observed at 48h
post-therapy at the maximum tolerated dose of 10mgkg
 1
doxorubicin. This relatively slow response to therapy is consistent
with that observed in cultured cells and reflects the relative
resistance of MDA-MB-231 tumours to genotoxic agents
(Fang et al, 2007). At 24h, after treatment with doxorubicin and
20s after the injection of hyperpolarised [1,4-
13C2]fumarate the
hyperpolarised
13C malate/fumarate ratio increased 5.4-fold
(Figure 5B), indicating the onset of tumour cell necrosis. At this
time point, a decrease in pyruvate–lactate exchange was also
observed, but did not reach significance. Therapy response was
observed earlier in tumours than in the cell experiments, with the
larger number of tumour cells in vivo giving an increase in
sensitivity.
The level of tumour cell death after drug treatment has been
shown, in preclinical and clinical studies, to be a good prognostic
indicator for treatment outcome, including in breast cancer
(Chang et al, 2000). However, early evidence of treatment response
does not necessarily indicate a favourable long-term outcome. For
example, an early decrease in FDG uptake in oesophageal
adenocarcinoma in the clinic following neoaduvant treatment
did not correlate with a histopathological response in the longer
term (Smithers et al, 2008) and in head and neck cancers treated
with radiotherapy uptake of l-[methyl-
11C]methionine was re-
duced, but there was no correlation with treatment outcome
(Nuutinen et al, 1999). However, in the case of the MDA-MB-231
human breast cancer model used in this study, a single treatment
with doxorubicin, at a slightly lower dose than used here, has been
shown to produce a long-term treatment response, as indicated by
a tumour growth delay of B20 days (Mason et al, 2008). Thus, the
imaging methods that we have described here can detect early
evidence of a treatment response that is correlated with outcome in
the longer term.
In summary, we have shown that hyperpolarised
13C experi-
ments for detecting early evidence of treatment response, which
had previously only been demonstrated in an implanted murine
lymphoma tumour model that responds very rapidly to treatment
with a genotoxic agent (Day et al, 2007; Witney et al, 2009), also
work in a human breast tumour xenograft that is much more
resistant to treatment with these agents. The hyperpolarised
[1-
13C]pyruvate experiment provided early evidence of a DNA
damage response, whereas the [1,4-
13C2]fumarate experiment
indicated the presence of tumour cell necrosis post-treatment.
Both experiments indicated the presence of a treatment response
in the absence of any change in tumour size. Translation of this
technique to the clinic could offer a new method for monitoring
treatment response in breast cancer.
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Figure 5 Detection of treatment response in implanted MDA-MB-231
tumours. Representative
13C spectra from untreated (upper spectra) or
doxorubicin-treated (lower spectra) tumours 20s post-injection of either
hyperpolarised [1-
13C]pyruvate (A), or hyperpolarised [1,4-
13C2]fumarate
(B). The peaks are: 1, [1-
13C]lactate; 2, [1-
13C]pyruvate hydrate; 3,
[1-
13C]alanine; 4, [1-
13C]pyruvate; 5, [1,4-
13C2]fumarate; 6, [1,4-
13C2]ma-
late. Spectra were taken 48 and 24h post-doxorubicin treatment for the
pyruvate and fumarate experiments, respectively.
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